doi: 10.1007/BF00258291.
High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy
- PMID: 455571
- DOI: 10.1007/BF00258291
Item in Clipboard
High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy
Cancer Chemother Pharmacol.
1979.
No abstract available
Similar articles
-
Current status of high dose progestin treatment in advanced breast cancer.Breast Cancer Res Treat. 1983;3(2):231-5. doi: 10.1007/BF01803566. Breast Cancer Res Treat. 1983. PMID: 6225476 Review.
-
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.Br J Cancer. 1984 Sep;50(3):363-6. doi: 10.1038/bjc.1984.184. Br J Cancer. 1984. PMID: 6235831 Free PMC article.
-
[High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].Med Welt. 1983 Mar 25;34(12):378-82. Med Welt. 1983. PMID: 6222235 German. No abstract available.
-
[High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].Onkologie. 1982 Aug;5 Suppl:13-6. Onkologie. 1982. PMID: 6215599 German.
-
[Estrogen antagonists and inhibitors in hormone therapy of breast cancer].Vopr Onkol. 1989;35(7):771-8. Vopr Onkol. 1989. PMID: 2528239 Review. Russian. No abstract available.
Cited by
-
Current status of high dose progestin treatment in advanced breast cancer.Breast Cancer Res Treat. 1983;3(2):231-5. doi: 10.1007/BF01803566. Breast Cancer Res Treat. 1983. PMID: 6225476 Review.
-
Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.Breast Cancer Res Treat. 1985;6(1):89-93. doi: 10.1007/BF01806014. Breast Cancer Res Treat. 1985. PMID: 4052636
-
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435103 Free PMC article.
-
Inhibition by medroxyprogesterone acetate of precancerous mammary hyperplastic alveolar nodule formation in mice.Breast Cancer Res Treat. 1985;5(1):31-6. doi: 10.1007/BF01807647. Breast Cancer Res Treat. 1985. PMID: 3156644
-
Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.Breast Cancer Res Treat. 1981;1(2):125-30. doi: 10.1007/BF01805865. Breast Cancer Res Treat. 1981. PMID: 6216931